Deciphering mechanism of anti-microbial action of non-antibiotic drugs Bupranolol and Propranolol against E. coli

Anshul Nigam, Rupal Gupta, Ananda Karthic

Abstract


Rise of Antibiotic resistance has prompted scientific community to refocus on search of novel antibiotics. Although, knowledge about antibacterial action of non-antibiotic drugs over pathogens is decades old. Almost, no attention was paid in developing novel class of antibiotics using them. β-adrenergic receptors Bupranolol and Propranolol are known to be active against E. coli although precise mechanism is unknown. It was speculated their antimicrobial action is via membrane proteins involved in transport of molecules, drug efflux pumps and energy generation. Therefore, we screened membrane proteome of E. coli in order to decipher precise mechanism and targets of antimicrobial action of these non-antimicrobial drugs. Our findings are in agreement with the notion regarding antimicrobial action mentioned above and following are identified as potential targets for repurposing of the two molecules which includes Drug efflux pump AcrB, lipid importer Blc, Beta barrel assembly machinery complex and ATP Synthase. 

References


Nigam A, Gupta D, Sharma A (2014) Treatment of infectious disease: beyond antibiotics. Microbiological research 169 (9-10):643-651.

Dong Y-H, Wang L-H, Zhang L-H (2007) Quorum-quenching microbial infections: mechanisms and implications. Philosophical Transactions of the Royal Society of London B: Biological Sciences 362 (1483):1201-1211.

Heinemann JA, Ankenbauer RG, Amábile-Cuevas CF (2000) Do antibiotics maintain antibiotic resistance? Drug discovery today 5 (5):195-204.

Descheemaeker P, Chapelle S, Lammens C, Hauchecorne M, Wijdooghe M, Vandamme P, Ieven M, Goossens H (2000) Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. Journal of antimicrobial chemotherapy 45 (2):167-173

Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Jama 298 (15):1763-1771.

Cetinkaya Y, Falk P, Mayhall CG (2000) Vancomycin-resistant enterococci. Clinical microbiology reviews 13 (4):686-707.

Berger-Bachi B (2002) Resistance mechanisms of gram-positive bacteria. International Journal of Medical Microbiology 292 (1):27

Williams J (1995) Selective toxicity and concordant pharmacodynamics of antibiotics and other drugs. Journal of Antimicrobial Chemotherapy 35 (6):721-737.

Kristiansen JE (1990) The antimicrobial activity of psychotherapeutic drugs and stereo-isomeric analogues. Danish Medical Bulletin 37 (2):165-182.

Jones G (1996) Successful cancer therapy with promethazine: the rationale. Medical hypotheses 46 (1):25-29.

Kristiansen JE (1992) The antimicrobial activity of non-antibiotics. Report from a congress on the antimicrobial effect of drugs other than antibiotics on bacteria, viruses, protozoa, and other organisms. APMIS Supplementum 30:7-14.

Kruszewska H, Zareba T, Tyski S (2004) Examination of antimicrobial activity of selected non-antibiotic drugs. Acta poloniae pharmaceutica 61:18-21.

Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R (1995) Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrobial agents and chemotherapy 39 (3):650-655.

Cederlund H, Mårdh P-A (1993) Antibacterial activities of non-antibiotic drugs. Journal of Antimicrobial Chemotherapy 32 (3):355-365.

Tyski S (2003) Non-antibiotics-drugs with additional antimicrobial activity. Acta poloniae pharmaceutica 60 (5):401-404.

Karami N, Nowrouzian F, Adlerberth I, Wold AE (2006) Tetracycline resistance in Escherichia coli and persistence in the infantile colonic microbiota. Antimicrobial agents and chemotherapy 50 (1):156-161.

Gonchar N, Partina I, Nyrkova O, Drap A (2014) Resistance of clinical strains of pathogenic E. coli to antibiotics and bacteriophage in hospitalized children with escherichiosis in St. Petersburg. Antibiotiki i khimioterapiia= Antibiotics and chemoterapy [sic] 59 (9-10):38-43.

Diekema DJ, BootsMiller BJ, Vaughn TE, Woolson RF, Yankey JW, Ernst EJ, Flach SD, Ward MM, Franciscus CL, Pfaller MA (2004) Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clinical infectious diseases 38 (1):78-85.

Ikram R, Psutka R, Carter A, Priest P (2015) An outbreak of multi-drug resistant Escherichia coli urinary tract infection in an elderly population: a case-control study of risk factors. BMC infectious diseases 15 (1):224.

Collignon P (2009) Editorial Commentary: Resistant Escherichia coli—We Are What We Eat. Clinical infectious diseases 49 (2):202-204.

Johnson JR, Sannes MR, Croy C, Johnston B, Clabots C, Kuskowski MA, Bender J, Smith KE, Winokur PL, Belongia EA (2007) Antimicrobial drug–resistant Escherichia coli from humans and poultry products, Minnesota and Wisconsin, 2002–2004. Emerging infectious diseases 13 (6):838.

Rasheed MU, Thajuddin N, Ahamed P, Teklemariam Z, Jamil K (2014) Antimicrobial drug resistance in strains of Escherichia coli isolated from food sources. Revista do Instituto de Medicina Tropical de São Paulo 56 (4):341-346.

Martin LJ, Piltonen MH, Gauthier J, Convertino M, Acland EL, Dokholyan NV, Mogil JS, Diatchenko L, Maixner W (2015) Differences in the antinociceptive effects and binding properties of propranolol and bupranolol enantiomers. The Journal of Pain 16 (12):1321-1333.

Takahashi N, Murota H, Sutoh I (1983) Antimicrobial activity of topical beta-adrenergic blocking agents. Ophthalmic research 15 (6):277-279.

Ejim L, Farha MA, Falconer SB, Wildenhain J, Coombes BK, Tyers M, Brown ED, Wright GD (2011) Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nature chemical biology 7 (6):348.

Burley SK, Berman HM, Bhikadiya C, Bi C, Chen L, Di Costanzo L, Christie C, Dalenberg K, Duarte JM, Dutta S (2018) RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy. Nucleic acids research 47 (D1):D464-D474.

Singh T, Biswas D, Jayaram B (2011) AADS-An automated active site identification, docking, and scoring protocol for protein targets based on physicochemical descriptors. Journal of chemical information and modeling 51 (10):2515-2527.

Rubenstein LA, Zauhar RJ, Lanzara RG (2006) Molecular dynamics of a biophysical model for β2-adrenergic and G protein-coupled receptor activation. Journal of Molecular Graphics and Modelling 25 (4):396-409.

Gaudet P, Livstone MS, Lewis SE, Thomas PD (2011) Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 12 (5):449-462.

Chung F-Z, Wang C-D, Potter P, Venter J, Fraser C (1988) Site-directed mutagenesis and continuous expression of human beta-adrenergic receptors. Identification of a conserved aspartate residue involved in agonist binding and receptor activation. Journal of Biological Chemistry 263 (9):4052-4055.

Deckers-Hebestreit G, Greie J-C, Stalz W-D, Altendorf K (2000) The ATP synthase of Escherichia coli: structure and function of F0 subunits. Biochimica et Biophysica Acta (BBA)-Bioenergetics 1458 (2-3):364-373.

Grzyb J, Latowski D, Strzałka K (2006) Lipocalins–a family portrait. Journal of plant physiology 163 (9):895-915.

Campanacci V, Bishop RE, Blangy S, Tegoni M, Cambillau C (2006) The membrane bound bacterial lipocalin Blc is a functional dimer with binding preference for lysophospholipids. FEBS letters 580 (20):4877-4883.

Bishop RE, Penfold SS, Frost LS, Höltje J-V, Weiner JH (1995) Stationary Phase Expression of a Novel Escherichia coli Outer Membrane Lipoprotein and Its Relationship with Mammalian Apolipoprotein D IMPLICATIONS FOR THE ORIGIN OF LIPOCALINS. Journal of Biological Chemistry 270 (39):23097-23103.

Bishop RE, Cambillau C, Privé GG, Hsi D, Tillo D, Tillier ER (2013) Bacterial Lipocalins: Origin, Structure, and Function. In: Madame Curie Bioscience Database [Internet]. Landes Bioscience,

Murakami S, Yamaguchi A (2003) Multidrug-exporting secondary transporters. Current opinion in structural biology 13 (4):443-452.

Saier Jr MH, Paulsen IT Phylogeny of multidrug transporters. In: Seminars in cell & developmental biology, 2001. vol 3. Elsevier, pp 205-213.

Pos KM (2009) Drug transport mechanism of the AcrB efflux pump. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1794 (5):782-793.

Paixão L, Rodrigues L, Couto I, Martins M, Fernandes P, De Carvalho CC, Monteiro GA, Sansonetty F, Amaral L, Viveiros M (2009) Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. Journal of Biological Engineering 3 (1):18.

Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A (2006) Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 443 (7108):173.

Su CC, Li M, Gu R, Takatsuka Y, McDermott G, Nikaido H, Yu EW (2006) Conformation of the AcrB multidrug efflux pump in mutants of the putative proton relay pathway. Journal of bacteriology 188 (20):7290-7296. doi:10.1128/jb.00684-06.

Knowles TJ, Scott-Tucker A, Overduin M, Henderson IR (2009) Membrane protein architects: the role of the BAM complex in outer membrane protein assembly. Nature Reviews Microbiology 7 (3):206.

Navarro-Garcia F (2019) Role of the BAM Complex in Outer Membrane Assembly. Biogenesis of Fatty Acids, Lipids and Membranes:651-669.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H (2018) Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555 (7698):623


Refbacks

  • There are currently no refbacks.


Published by:

 Indian Science and Technology Foundation (ISTF)

 C-1/31, Yamuna Vihar, New Delhi-110053 

Email: contact@isto-india.org

www.isto-india.org